Show simple item record

dc.contributor.authorJones, JA
dc.contributor.authorHillmen, P
dc.contributor.authorCoutre, S
dc.contributor.authorTam, C
dc.contributor.authorFurman, RR
dc.contributor.authorBarr, PM
dc.contributor.authorSchuster, SJ
dc.contributor.authorKipps, TJ
dc.contributor.authorFlinn, IW
dc.contributor.authorJaeger, U
dc.contributor.authorBurger, JA
dc.contributor.authorCheng, M
dc.contributor.authorNinomoto, J
dc.contributor.authorJames, DF
dc.contributor.authorByrd, JC
dc.contributor.authorO'Brien, SM
dc.date.accessioned2021-02-04T00:40:03Z
dc.date.available2021-02-04T00:40:03Z
dc.date.issued2017-07-01
dc.identifier.citationJones, J. A., Hillmen, P., Coutre, S., Tam, C., Furman, R. R., Barr, P. M., Schuster, S. J., Kipps, T. J., Flinn, I. W., Jaeger, U., Burger, J. A., Cheng, M., Ninomoto, J., James, D. F., Byrd, J. C. & O'Brien, S. M. (2017). Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. BRITISH JOURNAL OF HAEMATOLOGY, 178 (2), pp.286-291. https://doi.org/10.1111/bjh.14660.
dc.identifier.issn0007-1048
dc.identifier.urihttp://hdl.handle.net/11343/259160
dc.description.abstractBleeding events have been observed among a subgroup of chronic lymphocytic leukaemia (CLL) patients treated with ibrutinib. We analysed data from two studies of single-agent ibrutinib to better characterize bleeding events and pattern of anticoagulation and antiplatelet use. Among 327 ibrutinib-treated patients, concomitant anticoagulation (11%) or antiplatelet use (34%) was common, but major bleeding was infrequent (2%). Bleeding events were primarily grade 1, and infrequently (1%) led to discontinuation. Among 175 patients receiving concomitant anticoagulant or antiplatelet agents, 5 had major bleeding events (3%). These events were typically observed in conjunction with other factors, such as coexisting medical conditions and/or concurrent medications.
dc.languageEnglish
dc.publisherWILEY
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0
dc.titleUse of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib
dc.typeJournal Article
dc.identifier.doi10.1111/bjh.14660
melbourne.affiliation.departmentMedicine (St Vincent's)
melbourne.affiliation.facultyMedicine, Dentistry & Health Sciences
melbourne.source.titleBritish Journal of Haematology
melbourne.source.volume178
melbourne.source.issue2
melbourne.source.pages286-291
dc.rights.licenseCC BY-NC-ND
melbourne.elementsid1202692
melbourne.contributor.authorTam, Constantine
dc.identifier.eissn1365-2141
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record